摘要
洛匹那韦、利托那韦和利巴韦林是《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》的推荐药物。通过研究近年来洛匹那韦、利托那韦和利巴韦林临床药物分析的进展概况,重点关注药物在血浆中的多种测定方法,包括HPLC、LC-MS、MS、分光光度法、毛细管电泳法、免疫法等,为开展治疗药物监测工作提供参考。
Lopinavir, ritonavir and ribavirin are recommended in Diagnostic and Treatment Scheme for COVID-19(Trial Version 5). The research progress of clinical drug analysis of lopinavir, ritonavir and ribavirin in recent years is summarized. The focus is on a variety of methods for the determination of drugs in plasma, including HPLC, LC-MS, MS, spectrophotometry, capillary electrophoresis, immunoassay, etc., which provide a reference for the development of therapeutic drug monitoring.
作者
谢静
唐铭擎
丁立生
梁健
李羿
XIE Jing;TANG Mingqing;DING Lisheng;LIANG Jian;LI Yi(School of Pharmacy,Chengdu Medical College,Chengdu 610500,China;Chengdu Institute of Biology,Chinese Academy of Sciences,Chengdu 610041,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2020年第6期646-652,共7页
Chinese Journal of Modern Applied Pharmacy
基金
国家自然科学基金项目(21572219)
四川省卫生和计划生育委员会科研课题(18PJ549)
抗生素研究与再评价四川省重点实验室开放课题(ARRLKF19-13)。
